Home/Indications/Dermatology/Rosacea

Rosacea

Dermatology 0 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Treatments by Mechanism

Top 3 mechanisms across 4 industry trials with a known mechanism of action.

See full pipeline →

Tetracycline-class Drug

2 trials 1 sponsor

alpha adrenoceptor

1 trials 1 sponsor

Antiparasitic

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

52 industry-sponsored trials across 21 sponsors

View full landscape →

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Aclaris Therapeutics, Inc.	Oxymetazoline HCL 1.0% Cream	—	COMPLETED	2018-06-15	NCT03380390
Galderma R&D	Ivermectin 1% cream	—	COMPLETED	2018-02-08	NCT03075891
Galderma R&D	Brimonidine 0.33% gel (Br)	—	COMPLETED	2016-09	NCT02616250
Galderma R&D	Brimonidine	—	COMPLETED	2015-08	NCT02249065
Galderma R&D	Doxycycline	Tetracycline-class Drug [EPC]	COMPLETED	2013-06	NCT01426269
Galderma R&D	Doxycycline	Tetracycline-class Drug [EPC]	COMPLETED	2012-08	NCT01308619
Galderma R&D	doxycycline (Oracea®) 40 mg modified release as monotherapy	—	COMPLETED	2009-10	NCT00892281

Showing 20 of 20 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Actavis Inc.	Oxymetazoline Hydrochloride	alpha adrenoceptor	COMPLETED	2020-01-07	NCT03954444
Padagis LLC	Oxymetazoline	—	COMPLETED	2017-12-06	NCT03352323
Padagis LLC	Azelaic acid foam	—	COMPLETED	2017-10	NCT02800148
Maruho Co., Ltd.	Omiganan	—	COMPLETED	2017-07-14	NCT02576847
Maruho Co., Ltd.	CLS001 (Omiganan)	—	COMPLETED	2017-07-05	NCT02547441
Actavis Inc.	Generic Azelaic Acid Foam	—	COMPLETED	2017-06-22	NCT03287791
Maruho Co., Ltd.	CLS001 (Omiganan)	—	COMPLETED	2017-02-27	NCT02576860
Padagis LLC	Ivermectin	Antiparasitic [EPC]	COMPLETED	2017-02	NCT02795117
Padagis LLC	Brimonidine Topical Gel, 0.33 percent (Perrigo)	—	COMPLETED	2015-12	NCT02385240
AbbVie	Oxymetazoline HCL Cream 1.0%	—	COMPLETED	2015-08	NCT02095158
AbbVie	Oxymetazoline HCL Cream 1.0%	—	COMPLETED	2015-04	NCT02132117
Actavis Inc.	Brimonidine	—	COMPLETED	2014-12	NCT02289352
AbbVie	AGN-199201	—	COMPLETED	2014-11	NCT02131636
Actavis Inc.	Azelaic acid	—	COMPLETED	2014-09	NCT02120924
Galderma R&D	Brimonidine tartrate was applied cutaneously once daily for 8 days.	—	COMPLETED	2013-11-14	NCT01885000
Galderma R&D	Drug: CD07805/47 gel	—	COMPLETED	2013-10	NCT01789775
Galderma R&D	CD07805/47 gel 0.5%/CD07805/47 Vehicle	—	COMPLETED	2012-12	NCT01659853
Galderma R&D	CD07805/47 gel 0.5%	—	COMPLETED	2012-06	NCT01318733
Galderma R&D	CD07805/47 Gel	—	COMPLETED	2011-11	NCT01355471
Galderma R&D	CD07805/47 gel	—	COMPLETED	2011-09	NCT01355458

Showing 16 of 16 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
CAGE Bio Inc.	CGB-400	—	COMPLETED	2021-12-22	NCT04886739
Hovione Scientia Limited	1% Topical Minocycline Gel	—	COMPLETED	2019-03-01	NCT03263273
AOBiome LLC	B244	—	COMPLETED	2019-02-11	NCT03590366
Dr. Reddy's Laboratories Limited	DFD-29 Extended Release Capsules (40 mg)	—	COMPLETED	2018-11-07	NCT03340961
Dr. Reddy's Laboratories Limited	DFD-04 Ointment	—	COMPLETED	2017-01	NCT02828241
Vyne Therapeutics Inc.	FMX-103 1.5%	—	COMPLETED	2016-08	NCT02601963
Amorepacific Corporation	PAC-14028 cream 0.1%	—	COMPLETED	2016-08	NCT02583009
Galderma R&D	CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo	—	COMPLETED	2014-06	NCT02300129
Dermira, Inc.	DRM02	—	COMPLETED	2014-02	NCT01993446
AbbVie	AGN-199201 Dose A	—	COMPLETED	2013-05	NCT01735201
Sol-Gel Technologies, Ltd.	DER 45 EV	—	COMPLETED	2012-09	NCT00940992
Galderma R&D	CD07805/47 Gel	—	COMPLETED	2010-12	NCT01174030
Aria Aesthetics Inc.	Topical oxygen	—	COMPLETED	2010-01	NCT00991198
Coria Laboratories, Ltd.	tretinoin gel 0.05%	—	COMPLETED	2008-04	NCT00621218
Vyne Therapeutics Inc.	Topical Minocycline Foam FXFM244	—	TERMINATED	2014-03	NCT01134991
BioMimetix JV, LLC	BMX-010	—	SUSPENDED	2024-09	NCT03756389

Showing 9 of 9 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Humanis Saglık Anonim Sirketi	Ivermectin cream	—	COMPLETED	2024-07-11	NCT06557603
Journey Medical Corporation	Minocycline hydrochloride capsules	—	COMPLETED	2023-05-30	NCT05597462
CAGE Bio Inc.	CGB-400	—	COMPLETED	2019-04-18	NCT04508205
CAGE Bio Inc.	CGB-400	—	COMPLETED	2019-04-18	NCT04508660
Sun Pharmaceutical Industries, Inc.	Azelaic acid foam 15%	—	COMPLETED	2018-08-09	NCT03689010
Sun Pharmaceutical Industries, Inc.	Azelaic Acid 15% topical gel	—	COMPLETED	2017-03-31	NCT03094403
AbbVie	AGN-199201 Formulation A	—	COMPLETED	2012-06	NCT01579084
Sun Pharmaceutical Industries, Inc.	Metronidazole Topical Gel 1%	—	COMPLETED	2012-06	NCT01513863
Merck	Laropiprant	—	COMPLETED	2012-04	NCT01451619

Novel Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (13 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.